The FreeStyle Libre 2 system delivers clinical benefits for a broad range of patients.

MORE PATIENTS CAN DO IT WITHOUT LANCETS*
A major obstacle to glucose monitoring is the pain and hassle of finger pricks.\(^1,2\)

Patients do not test as often as they should, and many do not achieve optimal glycemic control\(^4-8\).

**Patient adherence to SMBG is low**

Only 1/3 adhere to the frequency of SMBG recommended by their HCP\(^1\)

2/3 skip SMBG because it is invasive to their lives\(^2\)

**Many patients fail to achieve their optimal glycemic control**

Many patients fail to achieve their optimal glycemic control

1/2 Canadians with diabetes do not achieve their A1C target of ≤7\(^%\)^\(^10\)

>3/4 using insulin do not achieve their A1C target of <7\(^%\)^\(^3\)

Infrequent glucose testing leads to insufficient glucose data for diabetes treatment decisions.\(^1,2\)

SMBG, self-monitoring of blood glucose.

* For diabetes patients using insulin more than once a day. For individuals with type 2 diabetes on once-daily insulin in addition to noninsulin antihyperglycemic agents, testing at least once a day at variable times is recommended. For individuals with type 2 diabetes not receiving insulin therapy, frequency of glucose testing recommendations should be individualized depending on type of antihyperglycemic agents, level of glycemic control, and risk of hypoglycemia.\(^3\)

**References:**

The FreeStyle Libre 2 system – now with optional alarms and no finger pricks*

**Reduces A1C**
Clinically proven to significantly reduce A1C in type 2 diabetes

**Easy to Use**
With a painless 1-second scan, patients see their current glucose reading, trend arrow, and 8-hour history

**Easy to Wear**
A small, discreet sensor that is easy to apply and comfortable to wear for up to 14 days

**Optional, Real-time Glucose Alarms**
Let patients know the minute their glucose is too low or too high

**Trusted Accuracy**
No confirmatory finger pricks required for treatment decisions – even when glucose is low, falling, or rapidly changing*

Data collected with the FreeStyle Libre system. The FreeStyle Libre 2 system has the same features as the FreeStyle Libre system but with optional real-time glucose alarms. Therefore, study data are applicable to both products.

* Finger pricks are required if readings do not match symptoms or expectations.

Increased glucose monitoring is strongly associated with better diabetes management. Data collected with the FreeStyle Libre system. The FreeStyle Libre 2 system has the same features as the FreeStyle Libre system but with optional real-time glucose alarms. Therefore, study data are applicable to both products.

References:
3. Ajjan R. Insights from real world use of flash continuous glucose monitoring. Presented at: American Diabetes Association 78th Scientific Sessions; June 22-26, 2018; Orlando, FL.
Patients with T2D on different therapies saw significant A1C reductions after using the FreeStyle Libre 2 system\textsuperscript{1,2}

**Patients on long-acting insulin\textsuperscript{2}**

Baseline
8.5%

Post
FreeStyle Libre 2 System
7.9% \quad (P < .0001)

**Significant A1C reduction in patients on long-acting (basal) insulin at 6 months**

RWD on change in A1C in patients with T2D taking long-acting insulin therapy after use of the FreeStyle Libre 2 system for 6 months (n = 277) and 12 months (n = 87)

In the 12-month group, patients using the FreeStyle Libre 2 system demonstrated significant A1C reduction of 0.5% (P = .0014)

**Patients on non-insulin therapies\textsuperscript{2}**

Baseline
8.5%

Post
FreeStyle Libre 2 System
7.6% \quad (P < .0001)

**Significant A1C reduction in patients on non-insulin therapies at 6 months**

RWD on change in A1C in patients with T2D taking non-insulin therapies (oral agents, GLP-1 receptor agonists) after use of the FreeStyle Libre 2 system for 6 months (n = 407) and 12 months (n = 120)

In the 12-month group, patients using the FreeStyle Libre 2 system demonstrated significant A1C reduction of 0.7% (P < .0001)

GLP-1, glucagon-like peptide 1; RWD, real-world data; T2D, type 2 diabetes.

Data collected with the FreeStyle Libre system. The FreeStyle Libre 2 system has the same features as the FreeStyle Libre system but with optional real-time glucose alarms. Therefore, study data are applicable to both products.

References:
Seamlessly manage your patients’ diabetes with free digital health tools

FreeStyle Libre 2

• Patients can use the FreeStyle Libre 2 app to easily share their glucose data with you

• Automatically uploads* glucose data to LibreView for easy HCP access

LibreView

• A secure cloud-based system that enables you to access reports on demand and virtually

Recommend the FreeStyle Libre 2 system to your patients today. Visit EasytoFreeStyle.ca to learn more.

LibreView is developed, distributed, and supported by Newyu, Inc. The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice. The LibreView website is only compatible with certain operating systems and browsers. Please check www.LibreView.com for additional information.

* Use of FreeStyle Libre 2 requires registration with LibreView. Automatic upload requires a wireless internet connection or mobile data connection.

© 2021 Abbott. FreeStyle, Libre, and related brand marks are marks of Abbott. Product images are for illustrative purposes only. Other trademarks are the property of their respective owners.

ADC-24761 v2.0